ArticleMolecular cancer therapeutics2017

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics.

Stuart W Ember et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.